"The voice of oncology in Massachusetts."

FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer

August 07, 2023 11:34 AM | Katy Monaco (Administrator)

Food and Drug Administration approved trifluridine and tipiracil (LONSURF, Taiho Oncology, Inc.) with bevacizumab, for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. FDA had previously approved single-agent LONSURF for this indication in September 2015.  Read More. 

View full prescribing information for LONSURF.

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software